These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8523234)

  • 41. Mass screening for neuroblastoma in Japan.
    Sawada T; Sugimoto T; Kawakatsu H; Matsumura T; Matsuda Y
    Pediatr Hematol Oncol; 1991; 8(2):93-109. PubMed ID: 1863547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stage and urinary catecholamine metabolite excretion in neuroblastoma. European Neuroblastoma Study Group.
    Pritchard J; Barnes J; Germond S; Hartman O; de Kraker J; Lewis I; Lockwood L; Wallendszus K
    Lancet; 1989 Aug; 2(8661):514-5. PubMed ID: 2570230
    [No Abstract]   [Full Text] [Related]  

  • 43. Urinary vanilmandelic acid and homovanillic acid: markers of two distinct cell populations in neuroblastoma?
    Mastrangelo R; Lasorella A; Iavarone A; Troncone L
    Pediatr Hematol Oncol; 1991; 8(4):379-81. PubMed ID: 1782120
    [No Abstract]   [Full Text] [Related]  

  • 44. Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan: lessons learned and future directions.
    Suita S
    J Pediatr Surg; 2002 Jul; 37(7):949-54. PubMed ID: 12077747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for neuroblastoma.
    Craft AW; Dale G
    Lancet; 1987 Nov; 2(8567):1082. PubMed ID: 2889984
    [No Abstract]   [Full Text] [Related]  

  • 46. Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations.
    Amano H; Uchida H; Harada K; Narita A; Fumino S; Yamada Y; Kumano S; Abe M; Ishigaki T; Sakairi M; Shirota C; Tainaka T; Sumida W; Yokota K; Makita S; Karakawa S; Mitani Y; Matsumoto S; Tomioka Y; Muramatsu H; Nishio N; Osawa T; Taguri M; Koh K; Tajiri T; Kato M; Matsumoto K; Takahashi Y; Hinoki A
    Cancer Sci; 2024 May; 115(5):1634-1645. PubMed ID: 38411285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mass screening for neuroblastoma and mortality in birth cohorts.
    Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Takasugi N
    Int J Cancer; 1997 May; 71(4):552-5. PubMed ID: 9178807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Problems of neuroblastoma screening for 6 month olds and results of second screening for 18 month olds.
    Hayashi Y; Ohi R; Yaoita S; Nakamura M; Kikuchi Y; Konno T; Tsuchiya S; Shiraishi H
    J Pediatr Surg; 1995 Mar; 30(3):467-70. PubMed ID: 7760244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thin-layer chromatography for diagnosis of secreting neuroblastoma.
    Ebinger G; Verheyden R; Maurus R
    Eur J Pediatr; 1975 Dec; 121(1):63-9. PubMed ID: 1213038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Screening for neuroblastoma in France: methodological aspects and preliminary observations.
    Chauvin F; Mathieu P; Frappaz D; Lasset C; Favrot MC; Greffe J; Esteve J; Thiesse P; Combaret V; Chauvot P; Boschetti R; David L; Brunat-Mentigny M; Philip T
    Med Pediatr Oncol; 1997 Feb; 28(2):81-91. PubMed ID: 8986143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.
    Scriver CR; Gregory D; Bernstein M; Clow CL; Weisdorf T; Dougherty GE; Auray-Blais C; Giguère R; Lemieux B; Laberge C
    CMAJ; 1987 May; 136(9):952-6. PubMed ID: 3105859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Establishment of cut off values for vanillylmandelic acid and homovanillic acid in 24-hr urine accumulation during mass screening for neuroblastoma.
    Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
    Jpn J Clin Oncol; 1987 Sep; 17(3):221-8. PubMed ID: 3669365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?".
    Flynn N; LeFebvre A; Messahel B; Hogg SL
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27248. PubMed ID: 29923309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Screening for neuroblastoma.
    Schilling FH; Erttmann R; Ambros PF; Strehl S; Christiansen H; Kovar H; Kabisch H; Treuner J
    Lancet; 1994 Oct; 344(8930):1157-8. PubMed ID: 7934514
    [No Abstract]   [Full Text] [Related]  

  • 55. Excretion of octopamine metabolites in neuroblastoma.
    Couch MW; Greer DM; Williams CM
    Clin Chim Acta; 1986 Jul; 158(1):109-14. PubMed ID: 3091293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
    Nishio N; Mimaya J; Nara T; Takashima Y; Horikoshi Y; Urushihara N; Hasegawa S; Aoki K; Hamasaki M
    Pediatr Int; 2006 Dec; 48(6):531-5. PubMed ID: 17168969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Vanillylmandelic acid (VMA) and homovanillic acid (HVA)].
    Kanesaka Y; Tomita K
    Nihon Rinsho; 1999 Dec; 57 Suppl():223-5. PubMed ID: 10778106
    [No Abstract]   [Full Text] [Related]  

  • 58. Imaging of neuroblastoma in patients identified by mass screening using urinary catecholamine metabolites.
    Tanabe M; Yoshida H; Ohnuma N; Iwai J; Takahashi H
    J Pediatr Surg; 1993 Apr; 28(4):617-21. PubMed ID: 8483079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A population-based study of the usefulness of screening for neuroblastoma.
    Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
    Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Screening for neuroblastoma.
    Lancet; 1987 Nov; 2(8569):1204. PubMed ID: 2890821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.